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Abstract
As lead has been shown to activate protein kinase C (PKC),
and gliomas are reported to be highly dependent on PKC for
their proliferation, this study was undertaken to investigate
whether lead may act as a mitogen in human astrocytoma
cells, and to determine the role of PKC in this effect. Lead
acetate (from 100 nM to 100 mM) induced a concentration- and
time-dependent increase in DNA synthesis, as measured by
incorporation of [methyl-
3H]thymidine into cell DNA, without
causing any cytotoxicity. Flow cytometric analysis showed
that lead was able to stimulate the cell cycle transition from the
G0/G1 phase to the S/G2 phase, resulting in increased
percentage of cells in the latter phase. Western blot analyses
showed that lead induced translocation of PKCa, but not of
PKC1 or PKCz, from the cytosolic to the particulate fraction,
with a concomitant increase in PKC enzyme activity.
Prolonged exposure to lead caused down-regulation of
PKCa, but not of PKC1. The effect of lead on DNA synthesis
was mediated through PKC as evidenced by the ®nding that
two PKC inhibitors, GF 109203X and staurosporine, as well as
down-regulation of PKC through prolonged treatment with
12-O-tetradecanoylphorbol 13-acetate, blocked lead-induced
DNA synthesis. Further experiments using a pseudosubstrate
peptide targeting classical PKCs and selective down-
regulation of speci®c PKC isoforms indicated that the effect
of lead on DNA synthesis was mediated by PKCa. Altogether,
these results suggest that lead stimulates DNA synthesis in
human astrocytoma cells by a mechanism that involves
activation of PKCa.
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Lead is a widespread environmental pollutant whose major
health concerns are developmental neurotoxicity and
carcinogenicity (ATSDR 1999; WHO 1995). The mechan-
isms of lead toxicity at the cellular and molecular level are
not fully understood, but strong evidence suggests that lead
interferes with signal transduction systems (Bressler and
Goldstein 1991; Costa 1998). A central hypothesis has been
that lead can interfere in cells with calcium-mediated
processes (Goldstein 1993; Simons 1993), and an enzyme
that has been studied in this regard is protein kinase C
(PKC).
PKC is a family of serine/threonine protein kinases which
can be subdivided into three groups: the classical PKC
members (a, bI, bII and g), which are calcium and
diacylglycerol-dependent; the novel PKCs (1, h, d and u)
which are calcium independent and diacylglycerol-
dependent; and the atypical PKCs (z, l and m) that are not
activated by calcium or diacylglycerol (Nishizuka 1995;
Mellor and Parker 1998). PKCs are translocated from the
cytosol to the membrane as part of their activation, and
typically phosphorylate serine or threonine residues on a
wide variety of proteins, including receptors, G proteins,
cytoskeletal proteins, protooncogene products and colleagues
(Liu 1996). Because of the large number of PKC
isozymes and of their substrates, the effect of PKC
activation can be multiple; affected functions include, for
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differentiation, apoptosis, and learning and memory pro-
cesses (Tanaka and Nishizuka 1994; Livneh and Fishman
1997; Van Der Zee and Douma 1997).
The interaction of lead with conventional PKCs has
received considerable attention since the ®nding that this
metal can activate PKC in immature rat brain microvessels
and in brain tissues, by mimicking calcium (Markovac and
Goldstein 1988a; 1988b). These ®ndings have been
con®rmed by several investigators in different cell types
and under different experimental conditions (Laterra et al.
1992; Long et al. 1994; Tomsig and Suszkiw 1995; Guity
and Pounds 1997; Schanne et al. 1997), though inhibitory
effects of lead have also been reported (Murakami et al.
1993; Tonner and Heiman 1997). Still, other studies have
found that lead may activate or inhibit PKC depending on
the concentration of free metal (Tomsig and Suszkiw 1995;
Sun et al. 1999). Activation of PKC by lead has been
suggested to be involved in its inhibition of astroglia-
induced microvessel formation (Laterra et al. 1992), to
contribute to its ability to release neurotransmitters from
bovine adrenal chromaf®n cells and PC12 cells (Tomsig and
Suszkiw 1995; Bressler et al. 1996), and to mediate lead-
induced rise in intracellular free calcium in osteoblastic
bone cells (Schanne et al. 1997).
In the present study, we investigated whether an
interaction of lead with PKC may lead to an increase in
cell proliferation. For this purpose, we utilized a human
astrocytoma cell line, which expresses the a, 1 and z
subtypes of PKC (Post et al. 1996). Several lines of evidence
indeed indicate that PKCs, and particularly PKCa, play a
relevant role in the proliferation of glioma cells (Couldwell
et al. 1991; Baltuch and Yong 1996). Glioma cells display
inherent high levels of PKC, particularly the a isozyme,
which correlates with their growth rate (Couldwell et al.
1991). Phorbol esters are potent mitogens in several glioma
cell lines (Guizzetti et al. 1996), and various PKC inhibitors,
as well as an antisense oligonucleotide to PKCa, inhibit
their proliferation (Ahmad et al. 1994). A study in which
much of this evidence was replicated in various glioma cell
lines concluded that signal transduction for proliferation of
glioma cells in vitro occurs predominantly through a PKC-
mediated pathway (Baltuch and Yong 1996). Thus, astro-
cytoma cells represent a good model to investigate the
interaction of lead and PKC in correlation with a speci®c
cellular response, i.e. cell proliferation.
Materials and methods
Materials
Dulbecco's modi®ed Eagle's medium (DMEM), fetal bovine serum
(FBS), penicillin/streptomycin and trypsin were purchased from
Gibco BRL (Grand Island, NY, USA). [Methyl-
3H]thymidine
(6.7 Ci/mmol) was from NEN (Boston, MA, USA). Polyclonal
antibodies to PKCa, PKC1, PKCz and the protease inhibitor
cocktail were from Boehringer Mannheim (Indianapolis, IN, USA).
Horseradish peroxidase-conjugated donkey anti-rabbit IgG anti-
body and the myristoylated PKC peptide inhibitor that is based
on the pseudosubstrate region for classical PKC (Myr-Arg-Phe-
Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val), were purchased
from Promega (Madison, WI, USA). Lead acetate and all other
chemicals were purchased from Sigma Chemical Co. (St Louis,
MO, USA). Lead acetate was dissolved in deionized water and
prepared as a 2-mm stock solution.
Culture of 1321N1 human astrocytoma cells
The human astrocytoma cell line 1321N1 (obtained from Dr J. H.
Brown, University of California at San Diego, CA, USA) was used
in all these studies. These cells were originally isolated from
primary cultures of cerebral glioma multiforme, and the 1321N1
cells are a subclone isolated in 1972 from a line designated 1181N1
(Foster and Perkins 1977). Cells were maintained in low-glucose
DMEM, supplemented with 5% FBS, 1 U/mL penicillin G and
1 mg/mL streptomycin in 75 cm
2 ¯asks under a humidi®ed
atmosphere of 5% CO2/95% air at 378C. Cells were subcultured
every 7 days, and the growth medium was changed every 3 or 4
days. Cells were seeded in 24-well plates at the density of
2.5  10
4/mL for the proliferation experiments, and in 100 mm
dishes at the density of 1  10
5/mL for western blot experiments.
Assays of cell proliferation
Incorporation of [methyl-
3H]thymidine into cell DNA was
measured as described previously (Guizzetti and Costa 1996;
Guizzetti et al. 1996). Brie¯y, cells were seeded at the density of
2.5  10
4/mL in 24-well plates. After 4 days in medium
supplemented with 5% FBS, cells were switched to serum-free
medium supplemented with 0.1% bovine serum albumin (BSA) for
48 h, before treatment. Treatment with lead or other compounds
was for 24 h. One mCi/well of [methyl-
3H]thymidine was included
for the last 6 h of the incubation at 378C under an atmosphere of
5% CO2/95% air. At the end of the incubation, cells were washed
twice with cold PBS and ®xed in methanol. Unincorporated
3H-
thymidine was removed by two washes with ice-cold 10%
trichloroacetic acid and one wash of ice-cold 0.5% trichloroacetic
acid. The monolayer was dissolved in 500 mLo f1mNaOH and
250 mL was transferred to scintillation ¯uid and counted for
radioactivity in a Beckman LS5000 CE scintillation counter.
Flow cytometric analysis was carried out using the double-
staining method with 5-bromodeoxyuridine (BrdU) and Hoechst
33258, developed by Rabinovitch et al. (1988), with slight
modi®cations (Guizzetti and Costa 1996). BrdU (150 mm) was
added to the medium together with agonists. After 48 h of
incubation with the agonist and BrdU, cells were harvested by
trypsin and centrifuged. The pellet was resuspended in 500 mLo fa
solution containing 0.154 m NaCl, 0.1 m Tris (pH 7.4), 0.5 mm
MgCl2, 0.2% BSA, 0.1% NP-40 and 5.9 mg/mL Hoechst 33258.
Ethidium bromide (1.5 mg/mL) was added 15 min before the
doubly stained cells (10 000 for each sample) were analyzed by
¯ow cytometry. Ultraviolet excitation was used with analysis of
Hoechst 33258 ¯uorescence at 350 nm and ethidium bromide
¯uorescence above 488 nm. Hoechst ¯uorescence emission was
recorded at 450 nm and ethidium bromide emission was measured
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using the MPLUS AV program (Phoenix Flow Systems, San Diego,
CA, USA).
Lactate dehydrogenase (LDH) release assay
After treatment, the medium was collected to measure the activity
of LDH using a kit from Sigma (St Louis, MO, USA). The kinetics
of the reduction of pyruvate and the oxidation of NADH were
evaluated as an index of LDH activity. Incubation with 0.1% Triton
X-100 for 4 h was used as positive control.
Western blot analysis of PKCs
Cells were seeded on 100-mm dishes in medium containing 5%
FBS, and were switched to serum-free medium when con¯uent.
Treatments were done after 48 h of serum starvation. After
treatment, cells were harvested in buffer containing Tris/HCl
20 mm (pH 7.4), EGTA 0.5 mm, b-mercaptoethanol 0.1% and a
protease inhibitor cocktail. Cells were broken by two cycles of
freezing and thawing, and the cytosolic and membrane fractions
were separated by centrifugation at 100 000 g for 20 min. The
supernatant was collected as cytosolic fraction. The pellet was
resuspended in a buffer containing Tris/HCl 20 mm (pH 7.4),
EGTA 2 mm, EDTA 10 mm, Triton-X 0.3%, b-mercaptoethanol
0.1% and protease inhibitors, shaken at 48C for 30 min, and
centrifuged at 15 000 g for 10 min. The supernatant was collected
as particulate fraction. To extract protein from whole cells, similar
processes without ultracentrifugation were carried out. Proteins
were quanti®ed using the Bradford's method, and a 5  sample
buffer was added. After boiling for 5±10 min, samples
containing 50 mg proteins were loaded on a 8% sodium dodecyl
sulfate±polyacrylamide gel (SDS±PAGE). After separation, pro-
teins were transferred to Immobilion membranes (Millipore,
Bedford, MA, USA), which were incubated in the presence of
polyclonal antibodies to PKCa, PKC1 or PKCz (dilution 1 : 1500)
and horseradish peroxidase-conjugated secondary antibody (dilu-
tion 1 : 2000). Bands were revealed by chemiluminescent
detection using the ECL kit (Amersham, Arlington Heights, IL,
USA), and densitometrically quanti®ed using a Millipore Image
System.
Measurement of protein kinase C activity
Activity of PKC was measured using a non-radioactive MESACUP
protein kinase assay kit from PanVera (Madison, WI, USA). The
kit is based on an enzyme-linked immunosorbent assay (ELISA)
that utilizes a synthetic PKC peptide (RFARKGSLRQKNV) coated
on microwell. The phosphorylation of the peptide was detected
through incubation with a biotinylated monoclonal antibody that
recognizes the phosphorylated form of the peptide and subsequent
incubation with streptavidin conjugated to peroxidase. Peroxidase
substrate was then added to the microwell and the intensity of the
Fig. 1 (a) Quiescent cultures of 132±1N1 astrocytoma cells were
exposed to different concentrations of lead (100 nM ± 100 mM)i n
serum-free medium for 24 h. During the last 6 h of incubation 1 mCi/
well of [methyl-
3H]thymidine was added as described in Materials
and methods. Data represent the means ^SEM of at least three
independent determinations. *p , 0.05, compared with control
group. (b) After serum deprivation, lead (5 mM) was added for the
indicated time periods; after washout with PBS, cells were shifted
back to serum-free medium. Data represent the means ^SEM of at
least three independent determinations. *p , 0.05, compared with
control group. (c) LDH activity in the medium after 24 h incubation in
the presence of different concentrations of lead. The maximal
leakage of LDH was measured after 4 h incubation with 0.1% Triton
X-100, a concentration that does not affect LDH activity. Enzymatic
activity is expressed as units/L. Data represent the means ^SEM of
at least four independent observations. *p , 0.01, signi®cantly
different from control.
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separating the membrane and the cytosol through ultracentrifuga-
tion, measurements were carried out according to the instruction of
the kit.
Statistical analysis
Each experiment was performed at least three times. All statistical
tests were carried out using the Statview 512 program (SAS
Institute Inc., Cary, NC, USA) or Microsoft Excel on a Macintosh
personal computer. One-way anova followed by Fisher's least
signi®cant difference test were used to determine signi®cant
difference between treatments.
Results
Lead induces DNA synthesis in human astrocytoma cells
Exposure to lead acetate (100 nm2100 mm) resulted in
concentration- and time-dependent increases in DNA
synthesis in human astrocytoma cells, as assessed by
3H-thymidine incorporation into DNA (Figs 1a and b).
The maximum increase was about 400% of basal, and
occurred after 6±18 h incubation with lead. Exposure to
different concentrations of lead for 24 h did not cause
any apparent cytotoxicity, as evidenced by a lack of
increase in LDH release in any of the lead treatment groups
(Fig. 1c).
Lead stimulates cell cycle progression
After 48 h of serum starvation (during which cells were
maintained in DMEM supplemented with 0.1% BSA), cells
were synchronized in the quiescent phase, as shown in
Fig. 2(a) and Table 1. Exposure to 20 mm lead for 48 h
stimulated cell cycle transition from the G0/G1 phase to the
Fig. 2 Representative ¯ow cytometry dia-
gram of cell distribution in the different
phases of cell cycle. (a) After serum depri-
vation, most of the cells are in the G0/G1
phase, with 2% of cells in the S/G2 phase,
and 1.9% in the new G0/G1 phase. (b) After
treatment with Pb (20 mM) for 48 h, a signi®-
cant percentage of the cells exit the G0/G1
phase and reenter the cell cycle, resulting
in a decreased percentage of cells in the
G0/G1 phase (to 56.3%), and an increased
percentage of cells in S/G2 phase (34.8%).
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the S/G2 phase, and a decreased percentage of cells in the
G0/G1 phase (Fig. 2, Table 1). Similar results were observed
after treatment with the phorbol ester 12-O-tetradecanoyl-
phorbol 13-acetate (TPA) (Table 1).
Effect of lead on PKC
Lead (10±100 mm, 30 min) was able to cause translocation
of PKCa, but not of PKC1 or PKCz, from the cytosolic to
the membrane fraction in human astrocytoma cells (Fig. 3a).
On the other hand, TPA induced the translocation of both
PKCa and PKC1, but not of PKCz. Treatment with lead or
TPA also resulted in an increase in membrane-associated
PKC activity and a corresponding decrease in cytosolic PKC
activity (Fig. 3b). Prolonged treatments with lead or TPA
for 24 h or 48 h resulted in down-regulation of PKCa,a s
measured by western blot of whole cell-extracted protein
(Fig. 4a). PKCa was reduced to 36 (^ 13)% of control after
24 h incubation with lead, and 14 (^ 6)% of control after
24 h incubation with TPA. TPA treatment for 24 h or 48 h
also down-regulated PKC1, while the effect of lead on this
isozyme was not statistically signi®cant (Fig. 4b).
PKC is involved in lead-induced DNA synthesis
To determine a possible PKC involvement in the mitogenic
effect of lead, two PKC inhibitors, staurosporine and GF
109203X, were tested for their ability to inhibit lead-induced
DNA synthesis in human astrocytoma cells (Fig. 5a). Both
compounds inhibited the effect of lead on DNA synthesis,
with IC50s of 0.41 ^ 0.08 nm and 754 ^ 120 nm for
staurosporine and GF109203X, respectively (n  3). Pre-
incubation with TPA for 24 h, which was shown earlier to
down-regulate PKC (Fig. 4), also abolished the proliferative
effect of lead (Fig. 5b).
PKCa is involved in lead-induced DNA synthesis
To further investigate the speci®c isoform of PKC involved
in lead-induced DNA synthesis, we used a myristoylated
PKC peptide inhibitor that is based on the pseudosubstrate
region for the classical PKCs (a and b). Since 1321N1
human astrocytoma cells express only the a, 1 and z
isozymes of PKC (Post et al. 1996), the pseudosubstrate
would be expected to target PKCa. Cells were pre-incubated
with the pseudosubstrate (25 mm) for 45 min before
treatment with lead. This pretreatment reduced PKC activity
to 50±70% of control (data not shown), and blocked the
ability of lead to stimulate DNA synthesis (Fig. 6a). When
cells were pre-incubated with 100 mm Pb for 24 h, a
treatment which leads to selective down-regulation of PKCa
(Fig. 4), the mitogenic effect of lead was also blocked
Fig. 3 (a) Representative immunoblots
showing the effect of lead on PKCa, PKC1
and PKCz translocation. Lane 1: control
(serum-deprived cells); lane 2±4: lead
10 mM,5 0 m M , 100 mM for 30 min; lane 5:
TPA 200 ng/mL, 30 min. Pb induced trans-
location of PKCa only, while TPA translo-
cated both PKCa and PKC1. Neither
compound had any effect on PKCz. (b) Pro-
tein kinase activity after treatment with lead
(100 mM, 30 min), or TPA (200 ng/mL,
30 min), was increased in the membrane
fraction, and decreased in the cytosolic
fraction. The measured activity re¯ects total
PKC activity and does not differentiate
among different subtypes of PKC. Data
represent the means ^SEM of three inde-
pendent experiments. *Signi®cantly different
from control, p , 0.05.
Table 1 Summary of cell cycle distribution from ¯ow cytometric
analysis
Percentage of cells in each phase
Treatment G0/G1 S/G2 New G0/G1
Control 96.3 ^ 0.3 2.0 ^ 0.2 1.9 ^ 0.1
Lead (20 mM) 56.3 ^ 4.7* 34.8 ^ 3.2* 8.9 ^ 1.5*
TPA (10 ng/mL) 59.7 ^ 2.4* 36.4 ^ 2.1* 3.9 ^ 1.2*
PDGF (25 ng/mL) 66.9 ^ 2.9* 12.8 ^ 1.4* 20.3 ^ 3.6*
Data are the means (^ SEM) of three separate experiments.
*Signi®cantly different from control, p , 0.05.
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dibenzoate (IDB; 50 nm for 24 h), which selectively
down-regulates PKC1 without affecting PKCa (Fig. 6c,
insert), did not affect the ability of lead to stimulate DNA
synthesis. On the other hand, the mitogenic effect of the
muscarinic agonist, carbachol, which has been shown to
stimulate DNA synthesis through activation of PKC1 and
PKCz (Guizzetti et al. 1998; Guizzetti and Costa, 2000),
was signi®cantly decreased by pretreatment with IDB
(Fig. 6c).
Fig. 4 Cultures of 1321N1 astrocytoma cells in serum-free medium
were exposed to 100 mM lead or 200 ng/mL TPA for 24 h or 48 h,
after which cells were harvested, and proteins were extracted from
whole cells. Levels of PKCa or PKC1 were measured by Western
blot. Results are expressed as percent of total optical density in
control cells after quanti®cation of the relative optical density (O.D.)
by densitometer. Data represent the means ^SEM of three
independent experiments. (a) Both lead and TPA down-regulated
PKCa after 24 or 48 h incubation. (b) TPA, but not lead, also down-
regulated PKC1 after 24 h or 48 h incubation. *Signi®cantly different
from control, p , 0.05.
Fig. 5 (a) DNA synthesis induced by lead (5 mM, 24 h) in human
astrocytoma cells was inhibited by two PKC inhibitors, staurosporine
and GF 109203X. The IC50 for staurosporine was 0.41(^ 0.08) nM,
and the IC50 for GF 109203X was 754 (^ 120) nM. Data represent
the means ^SEM of at least three independent determinations. (b)
Pretreatment with TPA abolished the mitogenic effect of lead. Cells
were Pre-incubated with TPA (200 ng/mL) for 24 h in serum-free
medium before addition of lead. The effect of lead (5 mM) on DNA
synthesis was inhibited by this Pre-incubation. Data represent the
means ^SEM of at least three independent determinations.
*p , 0.01, compared with treatment without Pre-incubation.
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synthesis
Carbachol (100 mm) alone stimulated DNA synthesis up to
500% of basal, as measured by
3H-thymidine incorp-
oration into DNA, con®rming previous observations
(Guizzetti et al. 1996, 1998; Guizzetti and Costa, 2000).
When cells were co-incubated with carbachol and lead, an
additive or synergistic effect on proliferation was observed
(Fig. 7).
Fig. 6 (a) Pre-incubation of astrocytoma cells with a pseudo-
substrate to PKCa for 45 min, inhibited the effect of lead (10 mM)
on DNA synthesis. *Signi®cantly different from control, p , 0.01.
(b) Pre-incubation of cells with lead (100 mM, 24 h), which was
shown to selectively down-regulate PKCa (Fig. 4), inhibited the
effect of lead on DNA synthesis. *p , 0.05, compared with the
effect of lead in control cells. (c) Pre-incubation of astrocytoma
cells with IDB (50 nM, 24 h) caused a down-regulation of PKC1,
but not of PKCa (inset). Under these conditions, the ability of
lead (5 mM) to stimulate DNA synthesis was not affected. On the
other hand, the mitogenic effect of carbachol was signi®cantly
reduced by this treatment. Data represent the means ^SEM of
three independent determinations. *p , 0.05, compared with the
effect in control cells.
Fig. 7 Carbachol (100 mM, 24 h) increased [methyl-
3H]thymidine
incorporation by about 500%. Co-incubation with lead (5 mM), which
alone caused a two-fold increase in DNA synthesis, potentiated the
mitogenic effect of carbachol. Data represent the means ^ SEM of
at least three independent determinations. *Signi®cantly different
from control, p , 0.05; **Signi®cantly different from carbachol alone,
p , 0.05.
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Results of this study indicate that lead acetate can stimulate
DNA synthesis in human 1321N1 astrocytoma cells by a
mechanism that involves activation of a classical PKC
isozyme, PKCa. The mitogenic effect of lead in these cells
is manifested through its ability to stimulate DNA synthesis,
measured by
3H-thymidine incorporation, and cell cycle
transition, as assayed by ¯ow cytometry. The effect of lead
was similar to that of the phorbol ester TPA, as both
compounds increased the number of cells in the S/G2 phase
to a greater extent than other mitogens such as PDGF or
carbachol (Table 1; Guizzetti and Costa 1996). TPA was,
however, a more potent inducer of DNA synthesis, as
indicated by a 20-fold stimulation of
3H-thymidine incor-
poration (Guizzetti et al. 1996), compared with 3±5-fold for
lead. A signi®cant increase in DNA synthesis was observed
at 5 mm lead acetate, with a maximal effect at 50 mm. None
of these concentrations of lead was associated with
cytotoxicity, as indicated by a lack of increase in LDH
release (Fig. 1), and by a lack of lead-induced apoptosis, as
measured by DNA laddering (not shown). This con®rms the
very low sensitivity of 1321N1 astrocytoma cells to lead
cytotoxicity, as reported by other investigators (Mead and
Pentreath 1998).
The effect of lead on DNA synthesis was antagonized by
two PKC inhibitors, GF109203X and staurosporine, and
by pretreatment of cells with TPA, which caused down-
regulation of PKCa and 1, suggesting an involvement of
PKC in the mitogenic effect of lead. Direct measurement of
activation of PKC isozymes indicated that lead could
stimulate translocation of the calcium-dependent PKCa,
but not of PKC1 or PKCz. Prolonged incubation with lead
also caused a selective down-regulation of the PKCa
isozyme. Under this condition, the effect of lead on DNA
synthesis was blocked. The pseudosubstrate peptide that
targets PKCa also inhibited lead-induced DNA synthesis.
However, when cells were pre-incubated with IDB, which
selectively down-regulates PKC1, lead retained its ability to
stimulate DNA synthesis. These observations indicate a
primary role of PKCa in the mitogenic action of this metal
in astrocytoma cells.
Lead-induced translocation of PKCa was observed at
concentrations slightly higher than those required to induce
DNA synthesis. For example, 10 mm lead acetate caused
only a small PKCa translocation (Fig. 3), but a three-fold
increase in
3H-thymidine incorporation into DNA (Fig. 1). It
should be noted, however, that for proliferation experiments
cells were incubated with lead for 24 h, while the PKC
translocation experiments were carried out after a 30-min
incubation, when maximal translocation was observed. Lead
has been shown to accumulate in astroglial cells, which are
thought to function as a lead sink, sequestering it from the
more sensitive neurons (Tiffany-Castiglioni et al. 1996).
The mechanism(s) by which lead enters astroglial cells are
not fully understood, but recent evidence suggests that it
may occur through l-type calcium channels (Legare et al.
1998), with a signi®cant accumulation of lead occurring
within the ®rst 24 h (Tiffany-Castiglioni et al. 1996).
The ®nding that, of the three PKC isozymes present
in human 1321N1 astrocytoma cells only the calcium-
dependent PKCa is activated by lead, suggests that lead may
either cause an increase in intracellular calcium, or may
directly activate the enzyme by mimicking calcium and
binding to the C2 domain of PKC (Rizo and Su Èdhof 1998).
Indeed, lead has been shown to increase intracellular
calcium levels in a number of cell types (Tiffany-Castiglioni
et al. 1996), and to substitute for calcium in activating PKC
(Markovac and Goldstein 1988b). Independently of the
exact molecular mechanism, activation of PKCa by lead
would represent only the ®rst step in the chain of events
that leads to cell proliferation. PKCa has been shown to
activate Raf-1 kinase, either by direct phosphorylation
(Kolch et al. 1993), or by modulating its membrane
association (Schonwasser et al. 1998). Raf-1, in turn, can
phosphorylate MEK (MAP kinase kinase; McDonald et al.
1993), which then activates the mitogen-activated protein
(MAP) kinases ERK1 and ERK2 (Lopez-Ilasaca 1998),
which play a central role in cell proliferation. In experiments
to be reported elsewhere, we have indeed found that lead
can activate the Raf-1/MEK/MAPK pathway in a PKCa-
dependent manner.
Co-incubation of astrocytoma cells with lead and the
muscarinic agonist carbachol provided some interesting
observations with important mechanistic implications.
Carbachol-induced proliferation of astrocytoma cells has
been shown to involve to a small extent PKC1 and to a
major degree PKCz, while PKCa seems to have a negligible
role (Guizzetti et al. 1998; Guizzetti and Costa, 2000). The
additive or even synergistic effect of lead and carbachol on
3H-thymidine incorporation, thus reinforces the hypothesis
that PKCa is a primary mediator of the effect of lead on
DNA synthesis.
Lead-induced increases in DNA synthesis had been
previously observed following in vitro exposure, as well
as after in vivo administration, but had not been investigated
in relationship to PKC activation. Hitzfeld et al. (1989)
found that lead increased DNA synthesis in rat kidney cells
in vitro. Interestingly, the effect of lead was abolished in
cells that had been `adapted' (i.e. pretreated) with lead,
suggesting a possible down-regulation of PKC under this
condition. Increased cell proliferation in rat kidney was also
reported following in vivo administration of lead (Choie and
Richter 1974). Similarly, administration of lead nitrate to
rats caused an increase of DNA synthesis in liver (Ledda-
Columbano et al. 1983; Liu et al. 1997). Lead also
stimulated the incorporation of [
3H]thymidine into cell
DNA in a dose-dependent manner in cultured vascular
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lead was recently shown to stimulate proliferation of rat
spleen lymphocytes in vitro (Razani-Boroujerdi et al. 1999).
The ability of lead to stimulate DNA synthesis in human
astrocytoma cells, in a manner similar to phorbol esters, may
have some relevance to the potential carcinogenicity of this
metal. Lead may have genotoxic properties, however, lead-
induced gene mutations in mammalian cells may not be the
result of direct damage to DNA, but rather, may occur by
indirect mechanisms, such as inhibition of DNA repair
(Zelikoff et al. 1988; Hartwig 1994). Lead is classi®ed by
IARC as a group 2B carcinogen (possible human carcino-
gen). In animals, there is evidence of lead inducing renal
adenocarcinomas and lung adenomas in mice, and cerebral
gliomas in rats (Oyasu et al. 1970; ATSDR 1999; WHO
1995). Excess of renal (Steenland et al. 1992), lung (Anttila
et al. 1995) and brain (Anttila et al. 1996; Cocco et al. 1998)
cancers have been found in epidemiological studies in lead-
exposed workers. In the study by Anttila et al. (1996), in
particular, an excess risk of gliomas (astrocytomas,
glioblastoma multiform and other gliomas), was observed
in workers exposed to lead, with a highly signi®cant odds
ratio of 11, for a blood lead level of 1.4 mm or above. In this
context, the ability of lead to stimulate DNA synthesis in
astrocytoma cells by activating PKCa, may be relevant and
worth further in vitro and in vivo investigations.
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